UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000037363
Receipt number R000042600
Scientific Title The Effects of Benzodiazepine and Orexin Receptor Antagonist on Cognitive Function Revealed by Auditory Event-related Potentials
Date of disclosure of the study information 2019/07/15
Last modified on 2019/07/13 15:49:01

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The Effects of Benzodiazepine and Orexin Receptor Antagonist on Cognitive Function Revealed by Auditory Event-related Potentials

Acronym

ERPs reflect BZ and suvorexant effects on cognition

Scientific Title

The Effects of Benzodiazepine and Orexin Receptor Antagonist on Cognitive Function Revealed by Auditory Event-related Potentials

Scientific Title:Acronym

ERPs reflect BZ and suvorexant effects on cognition

Region

Japan


Condition

Condition

Insomnia

Classification by specialty

Psychiatry Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The purpose of this study is to estimate the cognitive decline 1 day after oral medication with lormetazepam, a benzodiazepine, and suvorexant, an orexin receptor antagonist, by comparing mismatch negativity (MMN) and P300 reflecting auditory discrimination function.

Basic objectives2

Pharmacodynamics

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Individual mean amplitudes of mismatch negativity (MMN) and P300 1 day after oral administration of lormetazapam and suvorexant.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

3

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Receiving suvorexant 20 mg

Interventions/Control_2

Receiving lormetazepam 2 mg

Interventions/Control_3

Receiving placebo

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Healthy participants aged 20 years and older

Key exclusion criteria

History of mental illness and neurological disorder

Target sample size

60


Research contact person

Name of lead principal investigator

1st name Tetsuyta
Middle name
Last name Shiga

Organization

Fukushima Medical University

Division name

Department of Neuropsychiatry

Zip code

960-1295

Address

Hikarigaoka 1, Fukushima

TEL

024-547-1331

Email

tetsuya3@fmu.ac.jp


Public contact

Name of contact person

1st name Tetsuya
Middle name
Last name Shiga

Organization

Fukushima Medical University

Division name

Department of Neuropsychiatry

Zip code

960-1295

Address

Hikarigaoka 1, Fukushima

TEL

024-547-1331

Homepage URL


Email

tetsuya3@fmu.ac.jp


Sponsor or person

Institute

Fukushima Medical University

Institute

Department

Personal name



Funding Source

Organization

Fukushima Medical University

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethics Committee of Fukushima Medical University

Address

Hikarigaoka 1, Fukushima

Tel

024-547-1111

Email

rs@fmu.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 07 Month 15 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

60

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2016 Year 01 Month 01 Day

Date of IRB

2016 Year 01 Month 19 Day

Anticipated trial start date

2016 Year 02 Month 01 Day

Last follow-up date

2019 Year 01 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2019 Year 07 Month 13 Day

Last modified on

2019 Year 07 Month 13 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042600


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name